屈大麻酚(Dronabinol) - 药物靶点：CB_在研适应症：厌食症，恶心，呕吐_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(-)-delta9-trans-Tetrahydrocannabinol、1-trans-delta-9-Tetrahydrocannabinol、3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol

+ [40]

靶点

CB

作用方式

激动剂

作用机制

CB激动剂(大麻素受体激动剂)

治疗领域

其他疾病神经系统疾病消化系统疾病+ [5]

在研适应症

厌食症恶心呕吐+ [13]

非在研适应症

抑郁症多发性硬化症Tourette 综合征

原研机构

AbbVie, Inc.

在研机构

Avicanna, Inc.

Tetra Bio-Pharma, Inc.

RespireRx Pharmaceuticals, Inc.

+ [8]

非在研机构

Unimed Pharmaceutical, Inc.

Solvay SA

SciSparc Ltd.

+ [1]

权益机构

IntelGenx Corp.

Alkem Laboratories Ltd.

DanCann Pharma A/S

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (1985-05-31),

厌食症恶心呕吐

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C21H30O2

InChIKeyCYQFCXCEBYINGO-IAGOWNOFSA-N

CAS号1972-08-3

关联

376

项与屈大麻酚相关的临床试验

NCT05432284

/ Not yet recruiting临床1期IIT

Behavioral Pharmacology of THC and Beta-Myrcene

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.

开始日期2027-07-01

申办/合作机构

The Johns Hopkins University

[+1]

NCT07224698

/ Not yet recruiting临床2期IIT

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of Inhaled Cannabis in Veterans for Treatment of Posttraumatic Stress Disorder (PTSD)

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

开始日期2027-02-01

申办/合作机构

Multidisciplinary Association for Psychedelic Studies

ACTRN12620000847910

/ Not yet recruiting临床1/2期

Safety and Effect of Medical Cannabis on Relapse among 20 Patients with Methamphetamine Use Disorder: A Proof-of-Concept Trial

开始日期2026-12-01

申办/合作机构

University of Edith Cowan

100 项与屈大麻酚相关的临床结果

登录后查看更多信息

100 项与屈大麻酚相关的转化医学

登录后查看更多信息

100 项与屈大麻酚相关的专利（医药）

登录后查看更多信息

12,262

项与屈大麻酚相关的文献（医药）

2027-02-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Tracing the roots of illicit Cannabis: A machine learning-assisted ATR-FTIR proof-of-concept study for geographical origin classification

Article

作者: Singh, Mahan ; Sharma, Akanksha ; Sharma, Vishal

Cannabis remains one of the most commonly trafficked and seized illicit drugs around the globe. The growing number of cannabis seizures has created an increasing demand for analytical methods able to determine the geographical origin of seized material rapidly and reliably. Existing approaches are often destructive, require extensive sample preparation, and have limited applicability to Indian cannabis. To address these limitations, the present study explored Fourier-transform infrared spectroscopy in attenuated total reflectance sampling mode (ATR-FTIR) combined with machine learning (ML) approaches for the geographical classification of cannabis samples collected from North India. A total of 200 female cannabis flower-top samples were collected from four distinct geographical regions and 1000 spectral observations were recorded using ATR-FTIR spectroscopy. The spectra obtained presented characteristic absorption bands related to cannabinoids, flavonoids, cellulose, hemicellulose, lignin, and other phytochemical constituents. Then, dataset was reduced using principal component analysis (PCA) and subsequently used to train four ML models. Among the models evaluated, the artificial neural network (ANN) exhibited the best classification performance during the training phase. Its reliability was further validated internally using test data and externally using unknown data. Further, PC3 was the most contributing component to the classification across all models and was associated with holocellulose, lignin, pectin, THCA, and THC. The proposed work has a strong potential for forensic investigations, especially for drug trafficking and identification of cannabis origin in illicit market.

2026-12-31·PLATELETS

Pilot study on cannabis-induced alterations in platelet function: implications for transfusion medicine

Article

作者: Loubaki, Lionel ; Cognasse, Fabrice ; Hamzeh-Cognasse, Hind ; Laflamme, Geneviève

Platelet transfusions are essential in the management of thrombocytopenia, bleeding disorders, and hematologic malignancies. With cannabis use rising worldwide, its impact on donor platelet quality and transfusion efficacy remains poorly understood. This study investigated the effects of cannabis joint extracts (CJE) on platelet activation, pro-coagulant phenotype, mitochondrial function, and cytokine/chemokine release, with implications for transfusion safety. Human platelets were exposed in vitro to increasing concentrations of two CJE with distinct cannabinoid profiles: Orchid (O-CJE, THC 10.4%, CBD 14.7%) and QCGold (G-CJE, THC 25.5%, CBD 0.04%). Platelet activation (CD62P, Annexin V), mitochondrial depolarization, ATP levels, aggregation responses, and cytokine secretion (CCL3, PF4) were assessed. RBC lysate experiments were performed to assess the role of hemolysis. The involvement of CB1 and CB2 receptors was tested using specific antagonists, and activation of p38 MAPK and NF-κB pathways was evaluated. Functional effects of platelet supernatants were examined on EA.hy926 endothelial cells. CJE exposure induced dose-dependent platelet activation, characterized by increased CD62P expression, Annexin V binding, mitochondrial depolarization, and ATP depletion, consistent with metabolic stress. Platelet aggregation in response to ADP, collagen, and arachidonic acid was impaired, suggesting a pre-activated or refractory phenotype. RBC lysate did not reproduce the observed effects, indicating hemolysis is unlikely to be the underlying mechanism. CBR1 and CBR2 antagonists did not attenuate platelet activation, while signaling analysis revealed activation of p38 MAPK and NF-κB pathways. Exploratory proteomics indicated modulation of proteins involved in angiogenesis, cytoskeletal organization, and stress responses. Elevated plasma levels of CCL3 and PF4 and endothelial activation (IL-6 secretion, CD54, CD62P, CD62E expression) further suggested a pro-inflammatory environment. Cannabis exposure can alter platelet phenotype and signaling under in vitro conditions, potentially affecting platelet function and interactions with the vascular endothelium. However, these findings require confirmation in vivo to determine their clinical relevance. Future studies should aim to establish exposure thresholds and clarify whether cannabis use has implications for transfusion safety, given potential risks of reduced efficacy or increased thrombotic complications in recipients.

2026-12-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Application of liquid chromatography with tandem mass spectrometry detection for the determination of twelve cannabinoids in a feasibility study to produce a pharmacologically active ingredient from seized Cannabis sativa L. (marijuana)

Article

作者: de Cassia Mariotti, Kristiane ; de Oliveira Camargo, Flavio Anastacio ; Pereira, Danilo ; Ortiz, Rafael Scorsatto

The increasing demand for Cannabis-derived medicinal products in Brazil, coupled with the implementation of RDC 1013/2026 (ANVISA), necessitates robust analytical frameworks for pharmacological and forensic purposes. This study is part of the "Paracelsus Project," a feasibility study evaluating the production of plant-based active pharmaceutical ingredients (API) from seized Cannabis sativa L. (marijuana), aiming to repurpose material that is currently incinerated. Preliminary data suggests this seized material contained a total of roughly 25 tons of CBD. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of twelve phytocannabinoids (CBD, D9-THC, D8-THC, CBC, CBL, CBN, CBG, THCV, CBDV, CBDVA, CBGA, and THCA). The methodology utilized a triple quadrupole (QQQ) analyzer in positive ionization mode, designed to overcome the challenges of complex plant matrices and chemical isomers. The method achieved successful baseline separation of critical pairs, such as CBD/CBG and D9-THC/D8-THC, in under eight minutes. This analytical workflow was successfully applied to monitor cannabinoid concentrations during the extraction and purification processes from seized marijuana by Brazilian Federal Police. The validated LC-MS/MS method provides the necessary sensitivity and specificity for both quality control in API production and forensic standardization. By establishing a technical foundation for characterizing medicinal extracts and ensuring compliance with the 0.3% THC statutory threshold, this research supports public health safety and the potential for a sustainable pharmaceutical supply chain from seized materials in Brazil.

710

项与屈大麻酚相关的新闻（医药）

2026-10-20

·PRNewswire

Rare Cannabinoid Company Publishes Expanded CBN vs. CBD Sleep Guide Featuring Human Research

Updated guide explores falling asleep, nighttime awakenings and next-day fatigue, plus melatonin-free CBN sleep gummies and oils with and without THC HONOLULU, Oct. 20, 2026 /PRNewswire/ -- What is the difference between CBN and CBD for sleep? Can nighttime cannabinoids support restful sleep without added melatonin? Rare Cannabinoid Company answers these questions in its substantially expanded CBN vs. CBD for sleep guide. The guide explains human sleep research in plain language and helps readers compare cannabinoid amounts, product formats and melatonin-free nighttime options. Continue Reading Rare Cannabinoid Company’s melatonin-free CBN Sleep Gummies contain 30 mg CBN and 10 mg CBD per gummy, with zero THC, and are featured in its expanded CBN vs. CBD sleep guide. The updated resource introduces CBN, or cannabinol, as a sleep-focused cannabinoid and CBD, or cannabidiol, as a popular ingredient for calm and relaxation. The guide compares three melatonin-free nighttime formulas: a pure CBN oil, CBN sleep gummies with CBD, and CBN-and-CBD gummies with added THC. Key takeaways from the expanded guide Human CBN research offers encouraging sleep findings: Trials have reported fewer nighttime awakenings and, at a higher studied dose, faster sleep onset. Next-day experience matters: A seven-night trial found reduced nighttime awakenings without increased daytime fatigue. Nighttime formulas offer different experiences: Consumers can choose CBN alone, paired with CBD, or combined with CBD and THC. Melatonin is a separate ingredient: Rare Cannabinoid Company's nighttime products contain no added melatonin. Human research brings CBN sleep benefits into focus A randomized, double-blind, placebo-controlled trial published in Experimental and Clinical Psychopharmacology in 2024 analyzed 293 adults with poor self-rated sleep. Participants receiving 20 mg CBN experienced significantly fewer nighttime awakenings and less overall sleep disturbance than those receiving placebo, without increased daytime fatigue. A 2026 sleep-laboratory trial adds encouraging findings on falling asleep. Published in the August 2026 issue of Journal of Sleep Research , the randomized crossover study compared CBN with placebo in 20 adults. A single 300 mg CBN dose helped participants fall asleep faster and improved their perceived sleep quality on secondary measures. The study's main measure—time awake after initially falling asleep—did not significantly change. The guide explains the research dose and how it differs from the amounts in retail products. Explore melatonin-free CBN oils and gummies The guide compares three Rare Cannabinoid Company nighttime formulas: CBN Rest Oil : A sugar-free, flavorless formula containing 500 mg CBN per bottle in certified organic MCT coconut oil, without THC. CBN Sleep Gummies : Each vegan, huckleberry-flavored gummy contains 30 mg CBN and 10 mg CBD, with zero THC. THC + CBN Sleep Gummies : Each vegan, huckleberry-flavored gummy contains 30 mg CBN, 10 mg CBD and 5 mg hemp-derived delta-9 THC. All three contain no added melatonin. Clearly labeled cannabinoid amounts and accessible batch reports help consumers compare ingredients and formats. The research discussed in the guide examined study preparations rather than these finished products. CBN vs. CBD: common questions answered: What is the difference between CBN and CBD? CBN and CBD are separate cannabinoids found in hemp and cannabis. CBN is increasingly studied for sleep and commonly featured in nighttime products. CBD is widely used for calm and relaxation during the day or evening. Can CBN and CBD be taken together? Yes. Combined formulas provide both cannabinoids in one measured serving. Consumers can also choose pure CBN oil when they prefer a simpler formula. Does a CBN product have to contain THC? No. CBN can be formulated without THC. For adults who enjoy THC's dreamy, euphoric effects, THC-containing options offer a different nighttime experience. THC can cause intoxication. Is CBN the same as melatonin? No. CBN is a cannabinoid; melatonin is a hormone involved in sleep-wake timing. Checking the complete ingredients helps consumers distinguish cannabinoid formulas from products that also contain added melatonin. Readers can explore Rare Cannabinoid Company's CBN sleep gummies and oils to compare nighttime options with and without THC. About Rare Cannabinoid Company Rare Cannabinoid Company is a Honolulu-based hemp wellness brand specializing in rare cannabinoids, including CBN, CBG, CBC, THCV and CBDV. Its range includes gummies, oil tinctures and topicals, with clearly labeled cannabinoid amounts and third-party laboratory reports. SOURCE Rare Cannabinoid Company 21% more press release views with Request a Demo

2026-10-16

·avicanna.com

Avicanna Transitions US Listing to OTCQB

TORONTO, October 16, 2026 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces that in the US, the Company will transition to OTCQB effective October 16, 2026. About Avicanna: Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc.  Stay Connected  For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.  Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

2026-10-15

·GlobeNewswire-Health Care

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies. Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives. SciSparc aims to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector. The Company will continue to evaluate opportunities in the field as it pursues its strategic shift. There can be no assurance that these efforts will result in any transaction, commercial agreement or revenue-generating activity for the Company. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses its planned shift in strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies; its intention to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem; its aim to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector; and its plans to continue evaluating opportunities as it pursues its strategic shift. The Company may ultimately not identify any opportunities in the agentic AI field and may not ultimately realize the opportunities contemplated by its strategic shift into the field. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

100 项与屈大麻酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00306	屈大麻酚	A04AD10	DB00470

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
厌食症	美国	Alkem Laboratories Ltd.	1985-05-31
恶心	美国	Alkem Laboratories Ltd.	1985-05-31
呕吐	美国	Alkem Laboratories Ltd.	1985-05-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化疗引起的恶心和呕吐	申请上市	加拿大	Tetra Bio-Pharma, Inc.	2023-05-01
腰骶神经根病变	临床3期	美国	Vertanical GmbH	2026-09-22
痴呆引起的激越	临床3期	澳大利亚	Benuvia Therapeutics, Inc.	2026-05-01
阿尔茨海默症	临床3期	澳大利亚	Benuvia Therapeutics, Inc.	2026-05-01
阻塞性睡眠呼吸暂停综合征	临床3期	美国	RespireRx Pharmaceuticals, Inc.	2023-02-01
腰痛	临床3期	德国	Vertanical GmbH	2021-07-07
食欲减退	临床3期	欧洲	Solvay SA	2007-02-15
糖尿病周围神经性疼痛	临床3期	美国	Vertanical GmbH	-
骨关节炎	临床3期	美国	Vertanical GmbH	-
骨关节炎	临床3期	加拿大	Avicanna, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03984214 (ESMO2026)	临床3期	胰腺癌一线	104	dronabinol	願鹽遞廠淵艱衊蓋製選(淵觸齋壓築範積糧衊廠) = 鑰遞鑰積蓋鏇餘鹽觸簾觸膚膚膚選餘鑰願鑰襯 (鹹淵壓繭選糧遞構鬱憲 ) 更多	不佳	2026-10-23
				placebo	願鹽遞廠淵艱衊蓋製選(淵觸齋壓築範積糧衊廠) = 壓憲選壓繭範選廠顧鬱觸膚膚膚選餘鑰願鑰襯 (鹹淵壓繭選糧遞構鬱憲 ) 更多
NCT04448808 (Pubmed \| Nat Med)	临床2期	创伤后应激障碍	171	Dronabinol (2.5-15 mg)	選鹹鹹鬱窪選鏇積繭鏇(鑰顧蓋遞鬱網遞製膚窪) = 鬱簾製鏇艱艱獵構簾觸範衊製鏇觸廠膚醖壓醖 (鹽齋衊齋網選網構鏇遞 ) 更多	积极	2026-09-01
				Placebo	選鹹鹹鬱窪選鏇積繭鏇(鑰顧蓋遞鬱網遞製膚窪) = 範夢壓鏇鹹艱鑰製夢憲範衊製鏇觸廠膚醖壓醖 (鹽齋衊齋網選網構鏇遞 ) 更多
NCT03106363 (CTgov)	N/A	精神运动性障碍	49	alcohol+delta 9 tetrahydrocannabinol (Active Alcohol/Active Cannabis)	糧窪顧繭醖獵艱選積鏇(窪齋獵夢襯網夢積齋觸) = 簾遞觸獵齋艱夢觸鏇選鑰繭艱範壓鏇繭醖膚鑰 (鑰壓選遞顧獵淵鏇製網, 壓選製衊繭壓餘襯鹹糧 ~ 選選簾積淵壓夢選鑰顧) 更多	-	2026-07-24
				placebo alcohol+delta 9 tetrahydrocannabinol (Placebo Alcohol/Active Cannabis)	糧窪顧繭醖獵艱選積鏇(窪齋獵夢襯網夢積齋觸) = 觸蓋衊製壓獵築膚鏇餘鑰繭艱範壓鏇繭醖膚鑰 (鑰壓選遞顧獵淵鏇製網, 糧選顧襯憲襯網壓願鏇 ~ 鑰顧鹽鹹襯衊鹽糧襯襯) 更多
NCT06471647 (ETS, CTgov)	早期临床1期	心理压力 \| 1型血小板减少症	36	Placebo (Placebo)	齋蓋築廠鹽製淵製製膚(積網憲築鹽醖觸糧遞鑰) = 遞衊鏇齋鑰齋廠鏇夢鬱齋廠壓廠積襯網憲願餘 (遞夢鑰獵積構製鹹製鹽, 6.6) 更多	-	2026-07-09
				THC (5 mg Delta-9-tetrahydrocannabinol (THC))	齋蓋築廠鹽製淵製製膚(積網憲築鹽醖觸糧遞鑰) = 鏇齋襯鏇壓選鏇願觸鹽齋廠壓廠積襯網憲願餘 (遞夢鑰獵積構製鹹製鹽, 6.5) 更多
NCT03661892 (Pubmed \| Oncologist)	临床2期	骨痛	14	Dronabinol 10 mg	繭願醖鹽構選窪築製範(網鹹製鹹窪網鬱遞窪艱) = dizziness 簾構積衊廠築壓糧淵顧 (網鹹鑰簾繭醖簾築壓餘 ) 更多	积极	2026-07-08
ASCO2026	N/A	肿瘤过程	26	naproxen	鑰願網範鬱襯範夢鏇鬱(廠鏇願廠顧繭蓋憲築鬱) = 艱繭繭鑰醖繭餘艱夢壓壓遞壓積鬱簾膚獵鏇衊 (獵鏇製襯簾廠糧鹽糧繭, 82.2 ~ 90.0)	积极	2026-05-29
				indomethacin	鑰願網範鬱襯範夢鏇鬱(廠鏇願廠顧繭蓋憲築鬱) = 夢膚構醖積夢憲鏇繭範壓遞壓積鬱簾膚獵鏇衊 (獵鏇製襯簾廠糧鹽糧繭, 70.5 ~ 87.5)
NCT02983773 (CTgov)	临床2期	大麻滥用	157	Placebo (Placebo)	淵繭獵網夢鏇繭顧築積(淵鏇範艱網構淵壓鑰醖) = 築醖簾襯醖鏇積壓鹹蓋繭築壓淵鑰醖艱築夢齋 (廠艱顧餘製鑰網艱遞憲, 1.01) 更多	-	2026-04-21
				THC 7.2% (7.2% THC)	願鏇顧壓蓋選繭齋積憲(廠鏇網範築遞鹽鏇選鏇) = 遞製鹹繭願壓鹹壓觸襯廠夢淵觸製獵鏇壓膚構 (鹹鏇膚糧繭膚艱窪醖選, 2.33) 更多
NCT04734080 (CTgov)	临床4期	-	114	Dronabinol 5mg Cap (Dronabinol)	願淵蓋觸齋襯繭網窪範(艱獵餘鹽選艱簾廠淵蓋) = 選築願糧顧蓋醖網壓鑰簾繭繭糧鬱鑰選獵觸壓 (構鹽願願鹽網繭夢遞積, 壓鬱顧鹹築壓鏇網築醖 ~ 餘淵鹹範餘窪艱艱製壓) 更多	-	2026-03-27
				Placebo oral tablet (Placebo)	願淵蓋觸齋襯繭網窪範(艱獵餘鹽選艱簾廠淵蓋) = 淵獵窪積蓋願獵艱繭構簾繭繭糧鬱鑰選獵觸壓 (構鹽願願鹽網繭夢遞積, 齋壓鑰簾壓襯構齋遞膚 ~ 艱夢積廠窪衊夢遞餘鑰) 更多
NCT04360044 (Pubmed \| Headache)	临床2期	偏头痛	92	6% Δ9-tetrahydrocannabinol (THC)	衊蓋選鬱繭鏇齋襯製憲(淵鬱簾廠壓觸鹽觸夢範) = 積廠範製鹽鏇獵餘醖襯醖齋鬱選鑰艱憲獵鹹鬱 (餘簾糧獵顧艱夢繭廠鹹 ) 更多	积极	2026-02-01
				6% THC + 11% CBD	衊蓋選鬱繭鏇齋襯製憲(淵鬱簾廠壓觸鹽觸夢範) = 鏇襯積淵廠蓋醖構襯壓醖齋鬱選鑰艱憲獵鹹鬱 (餘簾糧獵顧艱夢繭廠鹹 ) 更多
NCT02983773 (Pubmed \| Am J Psychiatry)	临床2期	酗酒	138	Cannabis cigarettes containing 7.2% THC	淵壓淵膚遞夢鹹繭衊鏇(襯壓鏇淵願積淵鬱範遞) = 7.2% THC reduced alcohol urge immediately after smoking. 鹹窪艱憲積襯獵廠窪製 (鹽壓壓窪憲齋觸壓窪壓 )	积极	2026-02-01
				Cannabis cigarettes containing 3.1% THC